3D printed applicators for treating gynecologic cancers
Official title: Study of 3D-printed Custom Applicators for Intracavitary HDR Gynaecological Brachytherapy (DISCO)
Run by Royal North Shore Hospital · NCT06432478 · Data updated 2026-11-12
This study is testing whether 3D-printed custom applicators can make radiation treatment more effective for patients with gynecologic cancers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 10 (estimated) |
| Sponsor | Royal North Shore Hospital Academic / other |
| Locations | 1 site (St Leonards, New South Wales) |
| Status | Recruiting |
| Started | November 24, 2023 |
| Main results expected | September 2028 |
| Study ends | September 2028 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT06432478 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with FIGO stage I-IVA gynecologic cancers who are indicated for intracavitary brachytherapy.
✕Probably not a fit
Patients who are pregnant or have contraindications for brachytherapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the feasibility of using 3D-printed custom applicators for intracavitary brachytherapy in patients with gynecologic cancers. Traditional applicators can be complex and time-consuming to create, often leading to devices that do not meet design specifications. In contrast, 3D printing allows for the production of patient-specific applicators that are more efficient and cost-effective. The trial aims to assess the effectiveness of these custom applicators in delivering targeted radiation therapy to improve treatment outcomes.
Why it matters
Potential benefit: If successful, this approach could enhance the precision and effectiveness of brachytherapy for patients with gynecologic cancers.
How similar studies have gone: While the use of 3D printing in medical applications is gaining traction, this specific approach for brachytherapy in gynecologic cancers is novel and has not been widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to give informed consent * Patients indicated for intracavitary brachytherapy * FIGO stage I-IVA * ECOG 0-2 * Primary endometrial cancer, primary vaginal cancer, primary vulva cancer, recurrent gynaecological cancer Exclusion Criteria: * Pregnancy * Patients contraindicated for brachytherapy * Inflammatory bowel disease/history of adhesions/bowel obstruction * Renal transplant/horseshoe kidney * Patients with significant LVSI or pelvic sidewall invasion * Patients requiring interstitial brachytherapy implants
Where it's running
-
Royal North Shore Hospital
St Leonards, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Marita Morgia, MD — Royal North Shore Hospital
- Study coordinator: Marita Morgia, MD
- Email: Marita.Morgia@health.nsw.gov.au
- Phone: 9463 1300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Using Belzutifan to treat recurrent clear cell ovarian carcinoma
This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Using SCG142 TCR-T cells to treat HPV-related cancers
This study is testing a new type of immune cell treatment called SCG142 TCR-T cells to see if it can help people with advanced cancers related to HPV.
-
Evaluating mutations in solid tumors using liquid biopsy and genome sequencing
This study is trying to see if a blood test can find important gene changes in patients with advanced solid tumors to help doctors choose the best treatments for them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.